Ionis Pharmaceuticals subsidiary Akcea Therapeutics has received a non-binding recommendation from the Division of Metabolism and Endocrinology Products Advisory Committee at the US Food and Drug Administration (FDA), for the approval of Waylivra to treat familial chylomicronemia syndrome (FCS).

The FDA will consider the committee’s opinion while reviewing the New Drug Application submitted by Akcea.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Formulated using Ionis’s antisense technology, Waylivra is designed to minimise the production of ApoC-III protein, which is found in the liver and associated with plasma triglycerides regulation.

Akcea Therapeutics CEO Paula Soteropoulos said: “The committee’s majority vote in favour of approval is an important positive step to bring Waylivra to people with FCS who have no adequate treatment options.

“We are committed to the FCS community and will continue to focus on bringing Waylivra, potentially the first and only treatment, to people living with this disease.”

“We are committed to the FCS community and will continue to focus on bringing Waylivra, potentially the first and only treatment, to people living with this serious and potentially fatal disease.”

The committee’s decision is based on the results of two Phase III clinical trials and an open-label study that is currently underway.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In one trial. Waylivra achieved a statistically significant mean reduction in triglycerides of 77% from baseline and decreased risk of pancreatitis.

The most common adverse events observed during the trial were injection site reactions and platelet decline.

The drug is being studied in another Phase III study for familial partial lipodystrophy (FPL) patients. The data from this trial is expected to be reported next year.